Paper Q

Quality & Performance Report

Author: John Adler Sponsor: Chief Executive Date: IFPIC + QAC 24th Sept 2015

Executive Summary from CEO

Context

It has been agreed that I will provide a summary of the issues within the Q&P Report that I feel should particularly be brought to the attention of EPB, IFPIC and QAC. This complements the Exception Reports which are triggered automatically when identified thresholds are met.

Questions

- 1. What are the issues that I wish to draw to the attention of the committee?
- 2. Is the action being taken/planned sufficient to address the issues identified? If not, what further action should be taken?

Conclusion

<u>Good News:</u> Mortality the SHMI for January 14 to December 14 is 99, this is the best score that the Trust has achieved since the introduction of SHMI. Fractured NOF the standard has been achieved for the first time since July 2014 and the work of all involved should be commended. The RTT incomplete target remains compliant. Delayed transfers of care remain well within the tolerance. MRSA and avoidable Grade 4 pressure ulcers remain at zero. Cancer standards The 31 day treatment standard was achieved alongside the 62 day screening pathway. Cancelled operations was achieved in August, with half the number of operations cancelled on the day compared to July.

Bad News:

ED 4 hour performance in the calendar month of August was 90.6%, which has slipped slightly after being consistently over 92% for the last four months. It is 91.9% year to date. Grade 2 **pressure ulcers** were above the upper limit for the month. **C Diff** has increased to 6 this month, which is higher than the April and May lows but on track with the year to date trajectory. **RTT 52+ week waits** in Orthodontics continue given the difficulties with locum consultant recruitment. As referenced last month, problems in Endoscopy have had a big impact on **diagnostics 6 week wait** performance which is not expected to regain

compliance until October. The numbers have worsened as the longest waiting patients are being offered dates. **Cancer Standards** The 2 week wait standard was failed largely as a result of challenges in Endoscopy. **62 Day Cancer** has dropped considerably in July, however the number of backlog patients has reduced alongside this. You will notice we now report the 62 day standard tumour site by tumour site in the Quality & Performance report.

Input Sought

I recommend that the Committee:

- Commends the positive achievements noted under Good News
- Note the indicators highlighted in bold in the Conclusions section
- •

For Reference

Edit as appropriate:

1. The following objectives were considered when preparing this report:

Safe, high quality, patient centred healthcare	[Yes / No /Not applicable]
Effective, integrated emergency care	[Yes / No /Not applicable]
Consistently meeting national access standards	[Yes / No /Not applicable]
Integrated care in partnership with others	[Yes /No /Not applicable]
Enhanced delivery in research, innovation & ed'	[Yes / No /Not applicable]
A caring, professional, engaged workforce	[Yes / No /Not applicable]
Clinically sustainable services with excellent facilities	[Yes / No /Not applicable]
Financially sustainable NHS organisation	[Yes /No /Not applicable]
Enabled by excellent IM&T	[Yes /No /Not applicable]

2. This matter relates to the following governance initiatives:

Organisational Risk Register	[Yes /No /Not applicable]
Board Assurance Framework	[Yes / No /Not applicable]

3. Related Patient and Public Involvement actions taken, or to be taken: Not Applicable

4. Results of any Equality Impact Assessment, relating to this matter: Not Applicable

5. Scheduled date for the next paper on this topic: 29/10/15

Caring at its best

University Hospitals of Leicester

Quality and Performance Report

August 2015



One team shared values



CONTENTS

Page 2 Introduction and Performance Summary Page 3 New Indicators Indicators Removed Indicators where reporting methodology has been changed

<u>Dashboards</u>

- Page 4 Safe Domain Dashboard
- Page 5 Caring Domain Dashboard
- Page 6 Well Led Domain Dashboard
- Page 7 Effective Domain Dashboard
- Page 8 Responsive Domain Dashboard
- Page 9 Responsive Domain Cancer Dashboard
- Page 10 Compliance Forecast for Key Responsive Indicators
- Page 11 Research & Innovation UHL
- IHR Clinical Research Network: East Midlands
- Page 12 Estates & Facilities

Exception Reports

- Page 13 Clostridium Difficile
- Page 14 Avoidable Pressure Ulcers Grade 2
- Page 15 Outpatient Friends and Family Test Coverage
- Page 16 % Staff With An Annual Appraisal
- Page 17 52 Week Breaches Incompletes
- Page 18 6 Week Diagnostic Test Waiting Times
- Page 19 Cancelled patients not offered a date with 28 days of the cancellations UHL
- Page 20 NHS e-Referral System (formerly known as Choose and Book)
- Page 21 Ambulance Handovers
- Page 22 Cancer Waiting Times Performance
- Page 23 Cancer Patients Breaching 104 Days
- Page 24 CQC Intelligent Monitoring Report
- Page 26 15/16 Quality Schedule and CQUIN Indicators Confirmed RAGs for Q1 2015

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

- REPORT TO: INTEGRATED FINANCE, PERFORMANCE AND INVESTMENT COMMITTEE QUALITY ASSURANCE COMMITTEE
- DATE: 24TH SEPTEMBER 2015
- REPORT BY: ANDREW FURLONG, INTERIM MEDICAL DIRECTOR DARRYN KERR, DIRECTOR OF ESTATES AND FACILITIES RICHARD MITCHELL, DEPUTY CHIEF EXECUTIVE/CHIEF OPERATING OFFICER JULIE SMITH, CHIEF NURSE LOUISE TIBBERT, DIRECTOR OF WORKFORCE AND ORGANISATIONAL DEVELOPMENT

SUBJECT: AUGUST 2015 QUALITY & PERFORMANCE SUMMARY REPORT

1.0 Introduction

The following report provides an overview of the August 2015 Quality & Performance report highlighting TDA/UHL key metrics and escalation reports where required.

Domain	Page Number	Number of Indicators	Indicators with target to be confirmed	Number of Red Indicators this month
Safe	4	22	7	2
Caring	5	10	3	0
Well Led	6	18	6	3
Effective	7	16	3	1
Responsive	8	17	2	6
Responsive Cancer	9	9	1	3
Research – UHL	11	6	6	0
Research - Network	11	13	0	3
Estates & Facilities	12	10	0	1
Total		121	33	15

2.0 Performance Summary

3.0 New Indicators

Responsive

Cancer 62 day performance by tumour site is reported on the responsive cancer – page 9.

4.0 Indicators removed

Admitted and non-admitted RTT indicators have been removed.

5.0 Indicators where reporting methodology/thresholds have changed


Red RAG and Exception reporting thresholds have been amended to provide additional clarity.

Effective

Emergency readmissions within 30 days following an elective or emergency spell, has now been RAG rated based on local peer group analysis.

Responsive

Ambulance Handover reported from CAD+ from June onwards - data quality issues identified with EMAS data in that data is incomplete and there are duplicate records.



YTD

18

0

0

0

19

0

9

5.6

0

12

44

0

Safe

S19

indicators resulting in death or severe harm

JS

MD

Highest Decile

TDA

monthly target

NEW TDA INDICATOR - DEFINITION TO BE CONFIRMED



	KPI Ref	Indicators	Board Director	Lead Officer	15/16 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	13/14 Outturn	14/15 Outturn	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
	C1	Inpatients (Including Daycases) Friends and Family Test - % positive	JS	HL	Q1 95% Q2/3 96% Q4 97%	QC	Red if <95% ER if 2 mths Red	New Indicator	96%	97%	96%	97%	96%	96%	96%	96%	96%	97%	96%	96%	97%	96%	97%	96%
	C2	A&E Friends and Family Test - % positive	JS	HL	Q1 95% Q2/3 96% Q4 97%	QC	Red if <94% ER if 2 mths Red	New Indicator	96%	96%	92%	95%	96%	96%	96%	96%	96%	97%	96%	96%	96%	96%	97%	96%
	C3	Outpatients Friends and Family Test - % positive	JS	HL	Q1 95% Q2/3 96% Q4 97%	QC	Red if <90% ER if 2 mths Red			N	EW METH		GVEOR						94%	94%	93%	91%	93%	93%
D		Daycase Friends and Family Test - % positive	JS	HL	Q1 95% Q2/3 96% Q4 97%	QC	Red if <95% ER if 2 mths Red												96%	97%	97%	98%	98%	97%
arin	C5	Maternity Friends and Family Test - % positive	JS	HL	Q1 95% Q2/3 96% Q4 97%	QC	Red if <94% ER if 2 mths Red		96%	96%	96%	94%	96%	97%	95%	97%	96%	96%	95%	96%	95%	95%	96%	95%
ပ		Friends & Family staff survey: % of staff who would recommend the trust as place to receive treatment	LT	LT	Not within Lowest Decile	TDA	TBC	New Indicator	69.2%		67.2%			FFT not con al Survey ca			71.4%			68.7%				68.7%
	C7a	Complaints Rate per 100 bed days	AF	MD	TBC	UHL	TBC	New Indicator	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3
	C7b	Written Complaints Received Rate per 100 bed days	AF	MD	Not within Highest Decile	TDA	TBC						NEW T	'da Indi(CATOR -	DEFINITI	ON TO B	E CONFIF	RMED					
	C8	Complaints Re-Opened Rate	AF	MD	<=12%	UHL	Red if >=15% ER if >=15%	New Indicator	10%	11%	10%	9%	11%	11%	10%	17%	13%	11%	13%	7%	7%	7%	11%	9%
	CU	Single Sex Accommodation Breaches (patients affected)	JS	HL	0	TDA	Red / ER if >0	2	13	0	0	0	0	5	0	1	0	0	0	0	0	0	0	0



	KPI Ref	Indicators	Board Director	Lead Officer	15/16 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	13/14 Outturn	14/15 Outturn	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
	W1	Inpatients Friends and Family Test - Coverage (Adults and Children)	JS	HL	30%	TDA	Red if <26% ER if 2mths Red	NEW	/ METHO	DOLOGY	FOR CAL	CULATIN	IG COVEF	RAGE INC	LUDES A	DULTS AN	ND CHILD	REN	29.2%	30.5%	29.0%	27.7%	28.9%	29.0%
	W2	Daycase Friends and Family Test - Coverage (Adults and Children)	JS	HL	20%	TDA	Red if <8% ER if 2 mths Red	NEW	/ METHO	OOLOGY	FOR CAL	CULATIN	IG COVEF	RAGE INC	LUDES A	DULTS AN	ND CHILD	REN	12.5%	12.1%	15.5%	20.5%	23.8%	15.4%
	W3	A&E Friends and Family Test - Coverage	JS	HL	20%	TDA	Red if <10% ER if 2 mths Red	NEW	/ METHO	DOLOGY	FOR CAL	CULATIN	IG COVEF	RAGE INC	LUDES A	DULTS AN	ND CHILD	REN	14.7%	14.9%	13.3%	14.1%	13.3%	14.1%
	W4	Outpatients Friends and Family Test - Coverage	JS	HL	Q1 3% Q2/3 4% Q4 5%	UHL	Red if <2.5% ER if 2 mths Red	NEW	/ METHO	DOLOGY	FOR CAL	CULATIN	IG COVEF	RAGE INC	LUDES A	DULTS AN	ND CHILD	REN	1.3%	1.6%	1.2%	1.2%	1.4%	1.3%
	W5	Maternity Friends and Family Test - Coverage	JS	HL	30%	UHL	Red if <26% ER if 2 mths Red	25.2%	28.0%	29.2%	29.9%	18.7%	15.8%	21.7%	22.1%	25.8%	46.5%	40.2%	32.3%	35.8%	32.6%	25.6%	30.5%	31.3%
	W6	Friends & Family staff survey: % of staff who would recommend the trust as place to work	LT	вк	Not within Lowest Decile	TDA	ТВС	New Indicator	54.2%		53.7%		Q3 staff F National	FT not cor Survey ca	npleted as rried out		54.9%				52.5%			
	W7a	Nursing Vacancies	JS	мм	5% by Mar 16	UHL	Separate report submitted to QAC	N	EW UHL II	NDICATO	R	6.7%	6.7%	6.4%	6.0%	6.3%	5.5%	6.5%	8.5%	8.0%	7.3%	8.7%	8.9%	8.9%
Led	W7b	Nursing Vacancies in ESM CMG	JS	мм	5% by Mar 16	UHL	Separate report submitted to QAC	N	EW UHL II	NDICATO	R	10.8%	10.8%	10.7%	9.7%	12.8%	11.4%	14.0%	19.3%	13.0%	14.4%	13.3%	13.5%	13.5%
Well I	W8	Turnover Rate	LT	LG	Not within Lowest Decile	TDA	Red = 11% or above ER = Red for 3 Consecutive Mths	10.0%	11.5%	10.0%	1 0.5 %	10.3%	10.8%	10.7%	10.3%	10.1%	10.1%	11.5%	10.4%	10.5%	10.5%	10.6%	10.4%	10.4%
3	W9	Sickness absence	LT	кк	3%	UHL	Red if >4% ER if 3 consecutive mths >4.0%	3.4%	3.8%	3.4%	3.4%	3.7%	4.0%	4.0%	4.4%	4.2%	4.1%	4.0%	3.6%	3.4%	3.5%	3.5%		3.5%
	W10	Temporary costs and overtime as a % of total paybill	LT	LG	твс	TDA	ТВС	New Indicator	9.4%	8.5%	8.9%	8.5%	9.5%	9.0%	9.8%	10.5%	9.8%	11.5%	10.7%	10.2%	11.0%	10.8%	11.1%	10.8%
	W11	% of Staff with Annual Appraisal	LT	вк	95%	UHL	Red if <90% ER if 3 consecutive mths <90%	91.3%	91.4%	89.6%	88.6%	89.7%	91.8%	92.3%	92.5%	90.9%	91.0%	91.4%	90.1%	88.7%	89.0%	89.1%	88.8%	88.8%
	W12	Statutory and Mandatory Training	LT	вк	95%	UHL	ТВС	76%	95%	<mark>80%</mark>	83%	85%	86%	87%	89%	89%	90%	95%	93%	92%	<mark>92%</mark>	91%	91%	91%
	W13	% Corporate Induction attendance	LT	вк	95%	UHL	Red if <90% ER if 3 consecutive mths <90%	94.5%	100%	96%	98%	98%	98%	98%	100%	99%	100%	97%	97%	97%	98%	100%	97%	97%
	W14a	DAY Safety staffing fill rate - Average fill rate - registered nurses/midwives (%)	JS	мм	Not within Lowest Decile	TDA	ТВС		91.2%	87.7%	87.9%	91.6%	92.9%	91.3%	92.7%	94.3%	91.8%	91.0%	93.6%	90.3%	91.2%	90.3%	90.2%	91.1%
	W14b	DAY Safety staffing fill rate - Average fill rate - care staff (%)	JS	мм	Not within Lowest Decile	TDA	ТВС	New	94.0%	93.0%	94.8%	90.3%	95.4%	94.4%	95.8%	95.4%	92.8%	92.5%	94.2%	91.2%	93.5%	91.3%	92.4%	92.5%
	W14c	NIGHT Safety staffing fill rate - Average fill rate - registered nurses/midwives (%)	JS	мм	Not within Lowest Decile	TDA	ТВС	Indicator	94.9%	90.8%	91.4%	94.8%	97.4%	96.5%	96.4%	97.9%	96.5%	97.2%	98.9%	96.0%	96.2%	94.3%	94.3%	95.9%
	W14d	NIGHT Safety staffing fill rate - Average fill rate - care staff (%)	JS	мм	Not within Lowest Decile	TDA	твс		99.8%	97.9%	98.0%	97.8%	100.8%	101.2%	101.4%	103.6%	100.8%	103.2%	106.3%	98.7%	99.4%	101.2%	98.0%	100.7%

-

	KPI Ref	Indicators	Board Director	Lead Officer	15/16 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	13/14 Outturn	14/15 Outturn	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
	E1	Mortality - Published SHMI	AF	PR	Within Expected	TDA	Higher than Expected	105	103	106 (Jan13-D	ec13)	105 (J	Apr13-N	lar14)	103 (0ct13-S	ep14)		9	9 (Jan1	4-Dec 1	4)	
	E2	Mortality - Rolling 12 mths SHMI (as reported in HED) Rebased	AF	PR	Within Expected	QC	Red if >expected ER if >Expected or 3 consecutive mths increasing SHMI >100	105	97	104	103	103	102	102	100	100	100	99	99	97	Awaitir	ng HED	Update	97
	E3	Mortality HSMR (DFI Quarterly)	AF	PR	Within Expected	TDA	Red if >expected ER if >Expected or 3 consecutive increasing mths >100	88	94		92			93			93			Av	waiting [DFI Upda	ate	
	E4	Mortality - Rolling 12 mths HSMR (Rebased Monthly as reported in HED)	AF	PR	Within Expected	QC	Red if >expected ER if >Expected or 3 consecutive increasing mths >100	99	95	97	96	96	96	95	95	95	95	94	94	93	93		aiting Jpdate	93
	E5	Mortality - Monthly HSMR (Rebased Monthly as reported in HED)	AF	PR	Within Expected	QC	Red if >expected ER if >Expected or 3 consecutive increasing mths >100	91	94	85	96	97	95	88	96	99	98	85	82	95	97		ng HED date	91
	E6	Mortality - HSMR ALL Weekend Admissions - (DFI Quarterly)	AF	PR	Within Expected	QC	Red if >expected ER if >Expected or 3 consecutive increasing mths >100	96	101		103			97			103			Av	vaiting I	DFI Upd	ate	
ve	E7	Crude Mortality Rate Emergency Spells	AF	PR	Within Upper Decile	TDA	TBC	2.5%	2.4%	2.0%	1.9%	2.3%	2.1%	2.3%	3.0%	3.1%	2.7%	2.4%	2.1%	2.0%	2.3%	1.9%	2.0%	2.1%
Effective	E8	Deaths in low risk conditions (Risk Score)	AF	PR	Within Expected	TDA	Red if >expected ER if >Expected or 3 consecutive increasing mths >100	94	81	80	64	59	113	60	85	101	87	75	100	20	Awaitir	ng HED	Update	60
Ę		Emergency readmissions within 30 days following an elective or emergency spell	AF	IJ	Within Expected	UHL	Red if >7% ER if 3 consecutive mths >7%	7.9%	8.5%	8.4%	8.9%	8.4%	8.6%	8.9%	9.1%	8.2%	8.5%	8.5%	9.2%	9.1%	9.0%	8.8%		9.0%
	E10	No. of # Neck of femurs operated on 0-35 hrs - Based on Admissions	AF	RP	72% or above	QS	Red if <72% ER if 2 consecutive mths <72%	65.2%	61.4%	76.9%	59.0%	68.6%	69.6%	59.4%	57.3%	57.9%	67.2%	61.5%	55.7%	42.6%	70.1%	60.3%	78.1%	61.7%
	E11	Stroke - 90% of Stay on a Stroke Unit	RM	IL	80% or above	QS	Red if <80% ER if 2 consecutive mths <80%	83.2%	81.3%	78.1%	84.5%	83.2%	70.4%	73.3%	75.2%	82.5%	87.6%	83.3%	83.7%	84.5%	84.5%	84.8%		84.4%
	E12	Stroke - TIA Clinic within 24 Hours (Suspected High Risk TIA)	RM	IL	60% or above	QS	Red if <60% ER if 2 consecutive mths <60%	64.2%	71.2%	62.8%	65.5%	72.7%	67.8%	69.0%	83.5%	80.6%	64.0%	77.3%	86.3%	79.6%	72.0%	78.9%	80.2%	79.2%
	E13	Published Consultant Level Outcomes	AF	SH	>0 outside expected	QC	Red if >0 Quarterly ER if >0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	E14	Non compliance with 14/15 published NICE guidance	AF	SH	0	QC	Red if in mth >0 ER if 2 consecutive mths Red	New Indicator for 14/15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	E15	ROSC in Utstein Group	AF	PR	твс	TDA	TBC						NEW T		CATOR -	DEFINITI	ON TO B	E CONFI	RMED					
	E16	STEMI 150minutes	AF	PR	твс	TDA	твс						NEW T	DA INDI	CATOR -	DEFINITI	ON TO B	E CONFI	RMED					

-

Safe Caring Well Led Effective Responsive Research Estates and Facilities



	KPI Ref	Indicators	Board Director	Lead Officer	15/16 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	13/14 Outturn	14/15 Outturn	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
	R1	ED 4 Hour Waits UHL + UCC (Calendar Month)	RM	IL	95% or above	UHL	Red if <92% ER via ED TB report	88.4%	89.1%	91.0%	92.5%	91.3%	91.6%	89.8%	89.1%	83.0%	90.7%	89.6%	91.1%	92.0%	92.2%	92.6%	92.2%	90.6%	91.9%
	R2	12 hour trolley waits in A&E	RM	IL	0	TDA	Red if >0 ER via ED TB report	5	4	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0
	R3	RTT - Incomplete 92% in 18 Weeks	RM	WM	92% or above	TDA	Red /ER if <92%	92.1%	96.7%	94.0%	93.2%	94.0%	94.3%	94.8%	95.0%	95.1%	95.2%	96.2%	96.7%	96.6%	96.5%	96.2%	95.4%	94.6%	94.6%
	R4	RTT 52 Weeks+ Wait (Incompletes)	RM	WM	0	TDA	Red /ER if >0	0	0	0	15	1	3	3	2	0	0	0	0	0	66	242	256	258	258
	R5	6 Week - Diagnostic Test Waiting Times	RM	sк	1% or below	TDA	Red /ER if >1%	1.9%	0.9%	0.8%	0.7%	1.0%	1.0%	0.7%	1.8%	2.2%	5.0%	0.8%	0.9%	0.8%	0.6%	6.1%	10.9%	13.4%	13.4%
	R6	Urgent Operations Cancelled Twice	RM	PW	o	TDA	Red if >0 ER if >0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
e	R7	Cancelled patients not offered a date within 28 days of the cancellations UHL	RM	PW	0	TDA	Red if >2 ER if >0	85	33	1	2	1	2	2	0	3	4	3	1	2	0	1	1	5	9
onsiv	R8	Cancelled patients not offered a date within 28 days of the cancellations ALLIANCE	RM	PW	0	TDA	Red if >2 ER if >0	New Indicato for 14/15	[′] 11	0	0	6	0	0	1	1	2	1	0	0	0	1	0	0	1
spol	R9	% Operations cancelled for non-clinical reasons on or after the day of admission UHL	RM	PW	0.8% or below	Contract	Red if >0.9% ER if >0.8%	1.6%	0.9%	1.1%	0.7%	0.6%	0.8%	0.8%	1.2%	1.1%	0.8%	0.7%	1.0%	0.7%	0.5%	0.9%	1.3%	0.7%	0.9%
Re	R10	% Operations cancelled for non-clinical reasons on or after the day of admission ALLIANCE	RM	PW	0.8% or below	Contract	Red if >0.9% ER if >0.8%	1.6%	0.9%	0.3%	2.7%	0.0%	0.9%	1.0%	0.0%	0.8%	1.4%	0.0%	0.4%	1.2%	1.2%	1.0%	0.8%	0.0%	0.9%
	R11	% Operations cancelled for non-clinical reasons on or after the day of admission UHL + ALLIANCE	RM	PW	0.8% or below	Contract	Red if >0.9% ER if >0.8%	New Indicator for 14/15	0.9%	1.0%	0.9%	0.6%	0.8%	0.8%	1.1%	1.1%	0.8%	0.7%	0.9%	0.8%	0.6%	0.9%	1.3%	0.7%	0.9%
		No of Operations cancelled for non-clinical reasons on or after the day of admission UHL + ALLIANCE	RM	PW	N/A	UHL	TBC	1739	1071	98	94	55	90	94	108	102	85	64	98	79	56	97	138	67	437
	R13	Outpatient Hospital Cancellation Rates	RM	PW	Within Upper Decile	UHL	TBC							NEW TO	A INDICA	TOR - DE	FINITION	TO BE CO	ONFIRMED	D					
	R14	Delayed transfers of care	RM	PW	3.5% or below	TDA	Red if >3.5% ER if Red for 3 consecutive mths	4.1%	3.9%	4.0%	3.9%	3.9%	4.5%	4.6%	5.2%	3.9%	3.2%	2.9%	1.8%	1.2%	1.0%	1.5%	0.9%	1.2%	1.2%
	R15	NHS e-Referral (formally Choose and Book Slot Unavailability)	RM	wм	4% or below	Contract	Red if >4% ER if Red for 3 consecutive mths	13%	21%	26%	25%	26%	25%	20%	17%	16%	13%	19%	26%	34%	31%		Data Not	Available	9
	R16	Ambulance Handover >60 Mins (CAD+ from June 15)	RM	PW	0	Contract	Red if >0 ER if Red for 3 consecutive mths	New Indicato for 14/15	5%	2%	2%	1%	2%	5%	6%	10%	6%	11%	9%	6%	7%	7%	8%	9%	7%
	R17	Ambulance Handover >30 Mins and <60 mins (CAD+ from June 15)	RM	PW	0	Contract	Red if >0 ER if Red for 3 consecutive mths	New Indicato for 14/15	[′] 19%	12%	14%	15%	17%	25%	23%	25%	21%	21%	22%	22%	21%	17%	17%	17%	19%



RC22 Rare Cancers

RC23 Grand Total

RM

RM

ММ

ММ

85% or above

85% or above

TDA

TDA

Red if <90%

ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths

	(PI Ref	Indicators	Board Director	Lead	15/16 Target	Target Set	Red RAG/ Exception Report Threshold (ER)	13/14 Outturn	14/15 Outturn	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
I	Cance	r statistics are reported a month in arrears.				_,		Outturn	outum								1							<u> </u>
	RC1	Two week wait for an urgent GP referral for suspected cancer to date first seen for all suspected cancers	RM	мм	93% or above	TDA	Red if <93% ER if Red for 2 consecutive mths	94.8%	92.2%	92.2%	92.0%	90.6%	92.0%	92.5%	93.0%	92.2%	93.5%	91.5%	91.2%	87.9%	91.1%	87.5%	**	89.4%
-	RC2	Two Week Wait for Symptomatic Breast Patients (Cancer Not initially Suspected)	RM	ММ	93% or above	TDA	Red if <93% ER if Red for 2 consecutive mths	94.0%	94.1%	94.9%	94.4%	95.2%	98.6%	100.0%	93.0%	92.5%	91.5%	96.0%	99.0%	98.8%	87.2%	93.3%	**	94.6%
-	RC3	31-Day (Diagnosis To Treatment) Wait For First Treatment: All Cancers	RM	ММ	96% or above	TDA	Red if <96% ER if Red for 2 consecutive mths	98.1%	94.6%	94.4%	97.9%	91.9%	95.9%	92.5%	95.2%	91.7%	95.0%	97.0%	93.9%	97.9%	93.7%	97.2%	**	95.7%
	RC4	31-Day Wait For Second Or Subsequent Treatment: Anti Cancer Drug Treatments	RM	мм	98% or above	TDA	Red if <98% ER if Red for 2 consecutive mths	100.0%	99.4%	100.0%	98.8%	100.0%	97.1%	100.0%	96.7%	100.0%	100.0%	100.0%	100.0%	100.0%	97.7%	100.0%	**	99.3%
	RC5	31-Day Wait For Second Or Subsequent Treatment: Surgery	RM	мм	94% or above	TDA	Red if <94% ER if Red for 2 consecutive mths	96.0%	89.0%	90.1%	87.8%	94.0%	81.9%	82.4%	80.3%	89.2%	94.4%	87.5%	86.3%	92.2%	89.6%	92.2%	**	89.9%
	RC6	31-Day Wait For Second Or Subsequent Treatment: Radiotherapy Treatments	RM	мм	94% or above	TDA	Red if <94% ER if Red for 2 consecutive mths	98.2%	96.1%	97.3%	99.0%	96.5%	96.0%	94.7%	95.5%	87.6%	99.0%	100.0%	86.3%	98.1%	96.5%	95.9%	**	94.7%
	RC7	62-Day (Urgent GP Referral To Treatment) Wait For First Treatment: All Cancers	RM	мм	85% or above	TDA	Red if <85% ER if Red in mth or YTD	86.7%	81.4%	85.6%	78.8%	75.5%	80.4%	77.0%	84.8%	79.3%	78.9%	83.8%	75.7%	70.1%	84.2%	73.7%	**	76.1%
er	RC8	62-Day Wait For First Treatment From Consultant Screening Service Referral: All Cancers	RM	мм	90% or above	TDA	Red if <90% ER if Red for 2 consecutive mths	95.6%	84.5%	73.0%	100.0%	87.5%	75.0%	94.4%	93.8%	88.9%	79.4%	89.3%	91.7%	82.4%	93.3%	95.2%	**	90.8%
Cance	RC9	Cancer waiting 104 days	RM	мм	0	TDA	ТВС					NEW T	DA INDICA	ATOR					12	10	12	20	12	12
						1																		
>																								
	2-Day	Urgent GP Referral To Treatment) Wait For Firs	at Treatm	nent: All (Cancers Inc Rar	e Cancers													_					
on		(Urgent GP Referral To Treatment) Wait For Firs	Board Director	Lead Officer	Cancers Inc Rar	Target Set	Red RAG/ Exception Report Threshold (ER)	13/14 Outturn	14/15 Outturn	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
spon	(PI Ref		Board	Lead		Target Set				Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15 100.0%	Jun-15 	Jul-15	Aug-15	утр 100.0%
pon	(PI Ref	Indicators	Board Director	Lead Officer	15/16 Target	Target Set by	Threshold (ER) Red if <90%	Outturn	Outturn													Jul-15 91.4%		
espon	RC10 RC11	Indicators Brain/Central Nervous System	Board Director	Lead Officer MM	15/16 Target 85% or above	Target Set by TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0%	Outturn 	 91.1%									-	100.0%			**	100.0%
espon	KPI Ref RC10 RC11 RC12	Indicators Brain/Central Nervous System Breast	Board Director RM RM	Lead Officer MM MM	15/16 Target 85% or above 85% or above	Target Set by TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1%	Outturn 92.6%	 91.1%	 84.4%	 93.8%	 96.3%	 81.8% 75.0%	 100.0%	 93.3%	 97.4% 91.7%	 98.1%	 92.3%	100.0% 96.8%	 97.8%	 91.4%	**	100.0% 94.6%
espon	KPI Ref RC10 RC11 RC12	Indicators Brain/Central Nervous System Breast Gynaecological Haematological	Board Director RM RM RM	Lead Officer MM MM MM	15/16 Target 85% or above 85% or above 85% or above	Target Set by TDA TDA TDA TDA	Threshold (ER) Red if <00% ER if Red for 2 consecutive mths Red if <00% ER if Red for 2 consecutive mths Red if <00% ER if Red for 2 consecutive mths Red if <00%	Outturn 100.0% 96.1% 88.2%	Outturn 92.6% 77.5%	 91.1% 88.9%	 84.4% 91.7%	 93.8% 77.8%	 96.3% 71.4%	 81.8% 75.0%	 100.0% 66.7%	 93.3% 54.5%	 97.4% 91.7%	 98.1% 75.0%	 92.3% 64.3%	100.0% 96.8% 55.6%	 97.8% 66.7%	 91.4% 100.0%	** **	100.0% 94.6% 70.0%
espon	RC10 RC11 RC12 RC13 RC14	Indicators Brain/Central Nervous System Breast Gynaecological Haematological	Board Director RM RM RM RM	Lead Officer MM MM MM MM	15/16 Target 85% or above 85% or above 85% or above 85% or above	Target Set by TDA TDA TDA TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1% 88.2% 65.9%	Outturn 92.6% 77.5% 66.5%	 91.1% 88.9% 84.6%	 84.4% 91.7% 87.5%	 93.8% 77.8% 42.1%	 96.3% 71.4% 100.0%	 81.8% 75.0% 73.3% 	 100.0% 66.7% 75.0%	 93.3% 54.5% 66.7% 	 97.4% 91.7% 50.0% 87.5%	 98.1% 75.0% 80.0%	 92.3% 64.3% 50.0%	100.0% 96.8% 55.6% 55.0%	 97.8% 66.7% 83.3%	 91.4% 100.0% 37.5%	** ** ** **	100.0% 94.6% 70.0% 54.4%
espon	(PI Ref RC10 RC11 RC12 RC13 RC14 RC15	Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck	Board Director RM RM RM RM	Lead Officer MM MM MM MM	15/16 Target 85% or above	Target Set by TDA TDA TDA TDA TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1% 88.2% 65.9% 65.4%	Outturn 92.6% 77.5% 66.5% 69.9%	 91.1% 88.9% 84.6% 66.7%	 84.4% 91.7% 87.5% 83.3%	 93.8% 77.8% 42.1% 40.0%	 96.3% 71.4% 100.0% 100.0%	 81.8% 75.0% 73.3% 33.3%	 100.0% 66.7% 75.0% 77.8% 92.9%	 93.3% 54.5% 66.7% 70.0% 	 97.4% 91.7% 50.0% 87.5% 46.7%	 98.1% 75.0% 80.0% 62.5%	92.3% 64.3% 50.0% 75.0%	100.0% 96.8% 55.6% 55.0% 54.5%	 97.8% 66.7% 83.3% 66.7%	 91.4% 100.0% 37.5% 36.4%	** ** ** **	100.0% 94.6% 70.0% 54.4% 55.3%
espon	RC10 RC11 RC12 RC13 RC14 RC15 RC16	Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer	Board Director RM RM RM RM RM	Lead Officer MM MM MM MM MM	15/16 Target 85% or above	Target Set by TDA TDA TDA TDA TDA TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3%	Outturn 92.6% 77.5% 66.5% 69.9% 63.7%	 91.1% 88.9% 84.6% 66.7% 81.8% 70.0%	 84.4% 91.7% 87.5% 83.3% 50.0%	 93.8% 77.8% 42.1% 40.0%	 96.3% 71.4% 100.0% 56.3% 68.9%	81.8% 75.0% 73.3% 33.3% 62.5% 64.1%	 100.0% 66.7% 75.0% 77.8% 92.9% 74.4%	93.3% 54.5% 66.7% 70.0% 65.0%	 97.4% 91.7% 50.0% 87.5% 46.7%	 98.1% 75.0% 80.0% 62.5% 63.2% 88.6%	92.3% 64.3% 50.0% 75.0% 63.6%	100.0% 96.8% 55.6% 55.0% 54.5% 55.6%	 97.8% 66.7% 83.3% 66.7% 93.3%	 91.4% 100.0% 37.5% 36.4% 63.6%	** ** ** ** **	100.0% 94.6% 70.0% 54.4% 55.3% 69.1%
espon	RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC17	Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung	Board Director RM RM RM RM RM RM	Lead Officer MM MM MM MM MM MM	15/16 Target 85% or above	Target Set by TDA TDA TDA TDA TDA TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7%	Outturn 92.6% 77.5% 66.5% 69.9% 63.7% 69.9%	 91.1% 88.9% 84.6% 66.7% 81.8% 70.0%	 84.4% 91.7% 87.5% 83.3% 50.0% 48.1%	93.8% 93.8% 77.8% 42.1% 40.0% 50.0% 56.8%	 96.3% 71.4% 100.0% 56.3% 68.9%	81.8% 75.0% 73.3% 33.3% 62.5% 64.1%	 100.0% 66.7% 75.0% 77.8% 92.9% 74.4%	93.3% 54.5% 66.7% 70.0% 65.0%	97.4% 91.7% 50.0% 87.5% 46.7% 74.2%	 98.1% 75.0% 80.0% 62.5% 63.2% 88.6%	92.3% 64.3% 50.0% 75.0% 63.6% 84.6%	100.0% 96.8% 55.6% 55.0% 54.5% 55.6% 50.9%	 97.8% 66.7% 83.3% 66.7% 93.3% 74.6%	 91.4% 100.0% 37.5% 36.4% 63.6% 81.8%	** ** ** ** ** **	100.0% 94.6% 70.0% 54.4% 55.3% 69.1% 71.4%
espon	RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC16 RC17 RC18	Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung Other	Board Director RM RM RM RM RM RM RM	Lead Officer MM MM MM MM MM MM	15/16 Target 85% or above	Target Set by TDA TDA TDA TDA TDA TDA TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7% 78.7%	Outturn 92.6% 77.5% 66.5% 69.9% 63.7% 69.9% 95.0%	 91.1% 88.9% 84.6% 66.7% 81.8% 70.0% 100.0%	 84.4% 91.7% 87.5% 83.3% 50.0% 48.1%	 	 96.3% 71.4% 100.0% 56.3% 68.9%	81.8% 75.0% 73.3% 33.3% 62.5% 64.1%	 100.0% 66.7% 75.0% 77.8% 92.9% 74.4%	 93.3% 54.5% 66.7% 70.0% 65.0% 67.7% 100.0% 	97.4% 91.7% 50.0% 87.5% 46.7% 74.2%	 98.1% 75.0% 80.0% 62.5% 63.2% 88.6% 100.0%	92.3% 64.3% 50.0% 75.0% 63.6% 84.6% 50.0%	100.0% 96.8% 55.6% 55.0% 54.5% 55.6% 50.9%	 97.8% 66.7% 83.3% 66.7% 93.3% 74.6% 100%	 91.4% 100.0% 37.5% 36.4% 63.6% 81.8%	** ** ** ** ** **	100.0% 94.6% 70.0% 54.4% 55.3% 69.1% 71.4%
espon	RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC16 RC17 RC18	Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung Other Sarcoma Skin	Board Director RM RM RM RM RM RM RM RM	Lead Officer MM MM MM MM MM MM MM	15/16 Target 85% or above 85% or above	Target Set by TDA TDA TDA TDA TDA TDA TDA TDA TDA	Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90%	Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7% 78.7% 82.9%	Outturn 92.6% 77.5% 66.5% 63.7% 69.9% 95.0% 46.2%	 91.1% 88.9% 84.6% 66.7% 81.8% 70.0% 100.0%	 84.4% 91.7% 87.5% 83.3% 50.0% 48.1% 100.0% 		 96.3% 71.4% 100.0% 56.3% 68.9% 100.0% 	81.8% 75.0% 73.3% 33.3% 62.5% 64.1% 100.0% 0.0%	 100.0% 66.7% 75.0% 77.8% 92.9% 74.4% 100.0% 0.0%	 93.3% 54.5% 66.7% 70.0% 65.0% 67.7% 100.0% 	 97.4% 91.7% 50.0% 87.5% 46.7% 74.2% 100.0% 94.3%	 98.1% 75.0% 62.5% 63.2% 88.6% 100.0%	92.3% 64.3% 50.0% 75.0% 63.6% 84.6% 50.0% 66.7%	100.0% 96.8% 55.6% 55.0% 54.5% 55.6% 50.9% 100% 	 97.8% 66.7% 83.3% 66.7% 93.3% 74.6% 100%	 91.4% 100.0% 37.5% 36.4% 63.6% 81.8% 100% 	** ** ** ** ** ** **	100.0% 94.6% 70.0% 55.3% 69.1% 71.4% 80.0%
espon	RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC17 RC16 RC17 RC18 RC19 RC19	Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung Other Sarcoma Skin	Board Director RM RM RM RM RM RM RM RM	Lead Officer MM MM MM MM MM MM MM	15/16 Target 85% or above 85% or above	Target Set by TDA TDA TDA TDA TDA TDA TDA TDA TDA	Threshold (ER) Red if <00% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <00% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <00% ER if Red for 2 consecutive mths Red if <00%	Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7% 78.7% 82.9% 96.8%	Outturn 92.6% 77.5% 66.5% 63.7% 69.9% 95.0% 46.2% 96.7%	 91.1% 88.9% 84.6% 66.7% 81.8% 70.0% 100.0% 100.0% 52.6%	 84.4% 91.7% 83.3% 50.0% 48.1% 100.0%	 93.8% 77.8% 42.1% 50.0% 56.8% 66.7% 97.3%	 96.3% 71.4% 100.0% 56.3% 68.9% 100.0% 94.5%	 81.8% 75.0% 73.3% 33.3% 62.5% 64.1% 100.0% 98.4% 	 100.0% 66.7% 75.0% 92.9% 74.4% 100.0% 9.0% 94.1% 68.0%	93.3% 93.3% 54.5% 66.7% 65.0% 65.0% 67.7% 100.0% 100.0%	 97.4% 91.7% 50.0% 87.5% 46.7% 74.2% 100.0% 94.3% 77.8%	 98.1% 75.0% 80.0% 62.5% 63.2% 88.6% 100.0% 0.0%	92.3% 64.3% 50.0% 63.6% 84.6% 50.0% 66.7% 91.7%	100.0% 96.8% 55.6% 55.0% 55.6% 50.9% 100% 94.0%	 97.8% 66.7% 83.3% 66.7% 93.3% 74.6% 100% 100% 91.3%	 91.4% 100.0% 37.5% 36.4% 63.6% 81.8% 100% 93.8%	** ** ** ** ** ** **	100.0% 94.6% 70.0% 54.4% 55.3% 69.1% 71.4% 80.0% 92.8%

92.3% 84.6%

86.7% **81.4%**

100.0% 0.0% 100.0% 100.0% 100.0% 100.0% 66.7% 100.0%

85.6% 78.8% 75.5% 80.4% 77.0% 84.8% 79.3% 78.9% 83.7%

**

**

100% 100% 100%

75.7% 70.1% 84.2% 73.7%

100%

76.1%

Compliance Forecast for Key Responsive Indicators

Standard	August actual/ predicted	September predicted	Month by which to be compliant	RAG rating of required month delivery	Commentary
Emergency Care					
4+ hr Wait (95%) - Calendar month	90.6%				Weekly SITREPs have ceased from end of June. Future ED performance to be reported monthly.
Ambulance Handover (CAD)					
% Ambulance Handover >60 Mins (CAD+)			Not Agreed		Further meeting to be arranged as DQ is still an issue with missing data and
% Ambulance Handover >30 Mins and <60 mins (CAD+)			Not Agreed		duplicate records.
RTT (inc Alliance)					
Incomplete (92%)	94.6%	94.0%	Continued Delivery		July/August dip due to continuing growing pressure in ENT, General Surgery and Gastroenterology.
Diagnostic (inc Alliance)					
DM01 - diagnostics 6+ week waits (<1%)	13.4%	4.5%	October		Endoscopy the predominate cause of failure. Significant changes in endoscopy to support re-delivery. September predicted circa 4.5%.
# Neck of femurs					
% operated on within 36hrs (72%)	78.1%	72.0%	October		
Cancelled Ops (inc Alliance)					
Cancelled Ops (0.8%)	0.7%	0.8%	August		
Not Rebooked within 28 days (0 patients)	5	1	September		5 from Urology and 1 General Surgery and 1 HPB due to various capacity pressures
Cancer (predicted)					
Two Week Wait (93%)	88%	85%	November		
31 Day First Treatment (96%)	96%	96%	July		July and August expected to be compliant.
31 Day Subsequent Surgery Treatment (94%)	90%	92%	October		A one off issue in breast surgery has delayed recovery by 1 month.
62 Days (85%)	78%	75%	October (at risk)		Plans and backlog numbers are monitored weekly at the Cancer Action Board.



Research	

	KPI Ref	Indicators	Board Director	Lead Officer	14/15 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	YTD	Apr-15	May-15	Jun-15	YTD
	RU1	Median Days from submission to Trust approval (Portfolio)	AF	NB	TBC	твс	TBC		3.0			2.0			3.0			3.0		2.8		2.0		2.0
UHL	RU2	Median Days from submission to Trust approval (Non Portfolio)	AF	NB	TBC	твс	TBC		2.0			3.5			2.0			1.0		2.1		4.0		4.0
Research	RU3	Recruitment to Portfolio Studies	AF	NB	Aspirational target=10920/year (910/month)	твс	TBC	941	1092	963	1075	1235	900	1039	1048	604	1030	1043	1298	1022	1071	807	1025	968
Res	RU4	% Adjusted Trials Meeting 70 day Benchmark (data sunbmitted for the previous 12 month period)	AF	NB	TBC	твс	TBC	(Ju	113-Jun 43.4%	14)	(Oc	t13-Sep 70.5%		(No	ov13-De 70.5%	•	(A)	pr14-Ma	ar15) 86	5%				
	RU5	Rank No. Trials Submitted for 70 day Benchmark (data submitted for the previous 12 month period)	AF	NB	TBC	твс	TBC	•	113-Jun ank 17/0	'	•	t13-Sep ank 18/	•	•	ov13-De Rank 18/	•	(Apr14	4-Mar15) Rank (60/198				
	RU6	%Closed Commercial Trials Meeting Recruitment Target (data submitted for the previous 12 month period)	AF	NB	TBC	твс	TBC	(Ju	l13-Jun 50%	14)	(Oc	t13-Sep 52%	o14)	(No	ov13-De 48%	c14)	(Ap	or14-Mai	r 15) 38.	.6%				

	KPI Ref	Indicators	Board Director	Lead Director/Off icer	14/15 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	YTD	Apr-15	May-15	Jun-15
	RS1	Number of participants recruited in a reporting year into NIHR CRN Portfolio studies	AF	DR	England 650,000 East Midlands 50,000	NIHR CRN	Red / ER if <90%	92%	93%	94%	93%	91%	90%	101%	101%			
_	RS2a	A: Proportion of commercial contract studies achieving their recruitment target during their planned recruitment period.	AF	DR	England 80% East Midlands 80%	NIHR CRN	Red / ER if <60%	67%	64%	68%	54%	56%	47%	53%	53%			
WORK)	RS2b	B: Proportion of non-commercial studies achieving their recruitment target during their planned recruitment period	AF	DR	England 80% East Midlands 80%	NIHR CRN	Red / ER if <60%	81%	81%	73%	77%	77%	86%	75%	75%			
ž	RS3a	A: Number of new commercial contract studies entering the NIHR CRN Portfolio	AF	DR	600	NIHR CRN	TBC											
H NET	RS3b	B: Number of new commercial contract studies entering the NIHR CRN Portfolio as a percentage of the total commercial MHRA CTA approvals for Phase II-IV studies	AF	DR	75%	NIHR CRN	Red if <75%											
SEARCH	RS4	Proportion of eligible studies obtaining all NHS Permissions within 30 calendar days (from receipt of a valid complete application by NIHR CRN)	AF	DR	80%	NIHR CRN	Red if <80%	90%	89%	84%	82%	83%	83%	93%	93%			
RE	RS5a	A: Proportion of commercial contract studies achieving first participant recruited within 70 calendar days of NHS services receiving a valid research application or First Network Site Initiation Visit	AF	DR	80%	NIHR CRN	Red if <80%									the UI	present	utive
(CLINICAL	RS5b	B: Proportion of non-commercial studies achieving first participant recruited within 70 calendar days of NHS services receiving a valid research application	AF	DR	80%	NIHR CRN	Red if <80%										mance E 22/09/20	
	RS6a	A: Proportion of NHS Trusts recruiting each year into NIHR CRN Portfolio studies	AF	DR	England 99% East Midlands 99%	NIHR CRN	Red if <99%	81%	81%	81%	88%	88%	88%	94%	94%			
Research	RS6b	B: Proportion of NHS Trusts recruiting each year into NIHR CRN Portfolio commercial contract studies	AF	DR	England 70% East Midlands 70%	NIHR CRN	Red if <70%	56%	56%	56%	56%	56%	56%	56%	56%			
R	RS6c	B: Proportion of General Medical Practices recruiting each year into NIHR CRN Portfolio studies	AF	DR	England 25% East Midlands 25%	NIHR CRN	Red if <25%	45%	45%	51%	63%	54%	54%	61%	61%			
	R\$7	Number of participants recruited into Dementias and Neurodegeneration (DeNDRoN) studies on the NIHR CRN Portfolio	AF	DR	England 13500 East Midlands 510	NIHR CRN	Red if <510 Q4	325	438	448	532	624	729	1050	1050			
	RS8	Deliver robust financial management using appropriate tools - % of financial returns completed on time	AF	DR	England 100% East Midlands 100%	NIHR CRN	Red if <100%	100% *Q2		100	.0%		100%	100%	100%			

	Safe Caring Well Led Effective	Resp	oonsive	Research	Estates and Facilities		-													
	KPI Ref Indicators	Board Director	Lead Officer	14/15 Target	Target Set by	Red RAG/ Exception Report Threshold (ER)	14/15 Outturn	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	YTD
	Percentage of statutory inspection and testing E&F1 completed in the Contract Month measured against the PPM schedule.	рк	GL	100%	Contract KPI	Red if ≤ 98%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		100.0%
	E&F2 Percentage of non-statutory PPM completed in the Contract Month measured against the PPM schedule	DK	GL	100%	Contract KPI	Red if ≤ 80%	100.0%	91.5%	81.2%	95.6%	80.5%	86.6%	97.4%	99.5%	99.0%	99.0%	98.0%	83.0%		94.8%
es	E&F3 Percentage of Estates Urgent requests achieving rectification time	DK	LT	95%	Contract KPI	Red if ≤ 75%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		100.0%
acilitie	E&F4 Percentage of scheduled Portering tasks completed in the Contract Month	DK	LT	99%	Contract KPI	Red if ≤ 98%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		100.0%
and F	E&F5 Number of Emergency Portering requests achieving response time	DK	LT	100%	Contract KPI	Red if >2	0	0	0	0	0	0	0	0	0	0	0	0	New dashboard	0
states	E&F6 Number of Urgent Portering requests achieving response time	DK	LT	95%	Contract KPI	Red if ≤ 95%	95.0%	95.1%	96.2%	97.3%	97.2%	97.2%	98.5%	98.1%	99.0%	100.0%	100.0%	100.0%	currently under development	99.8%
	E&F7 Percentage of Cleaning audits in clinical areas achieving NCS audit scores for cleaning above 90%	DK	LT	100%	Contract KPI	Red if ≤ 98%	<mark>100.0%</mark>	100.0%	99.1%	100.0%	100.0%	100.0%	94.4%	96.1%	97.0%	95.0%	95.0%	93.0%	development	95.0%
	E&F8 Percentage of Cleaning Rapid Response requests achieving rectification time	DK	LT	92%	Contract KPI	Red if ≤ 80%	92.0%	99.6%	89.9%	93.3%	90.5%	91.1%	94.1%	96.9%	95.0%	95.0%	100.0%	99.0%		97.3%
	E&F9 Percentage of meals delivered to wards in time for the designated meal service as per agreed schedules	DK	LT	97%	Contract KPI	Red if ≤ 95%	97.0%	99.4%	99.5%	100.0%	100.0%	98.9%	99.9%	100.0%	100.0%	100.0%	100.0%	99.0%		99.8%
	E&F10 Overall percentage score for monthly patients satisfaction survey for catering service	DK	LT	85%	Contract KPI	Red if ≤ 75%	85.0%	96.7%	97.3%	97.3%	96.7%	93.8%	95.8%	97.5%	96.0%	97.0%	91.0%	91.0%		93.8%

Clostridium Difficile

What is causing underperformance?	What actions have been taken to improve performance?	Target (mt end of yea				nonth ance		YTD performance				Forecast performar for next reporting period			
The cases of CDT are currently subject to Post Infection Reviews	Any learning following the outcome of the PIRs should be presented to the							18						N/A	
as C difficile infection reported on the death certificate have been	CMG Infection Prevention Groups and should follow the PIR process		Apr	Мау	Jun	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb	Mar	Total
identified recently.	flow chart as described in the Infection Prevention Toolkit. Action	Trajectory 15/16	5	5	5	5	5	5	5	5	5	6	5	5	61
There are no discernible factors that link the 6 cases in August to	plans with named local leads will be produced if the PIR feels action is	Actual Infections 15/16	3	1	4	4	6								18
 people and place, and they should be viewed in the context of being only 35% of the cases reported in August, and the trust is still below trajectory overall. Additionally upon clinical review 2 of the cases were deemed not be true infection and coincidental identification of C difficile which may represent colonisation. Concerns in relation to compliance with the National Minimum Cleaning frequencies have been expressed from colleagues within all CMGs and continue to be reported to the facilities management team and monitored locally. 	required to reduce further cases. The number of cases to date mirrors last year's numbers at this time however we continue to strive for a further reduction in cases. The Director of Facilities will chair a newly formed monthly Infection Prevention Operational Group who in conjunction with a quarterly TIPAC have as their remit the review of current cleanliness forums in place, to ensure these are fit for purpose and are monitoring cleanliness and ensuring performance delivery effectively.	70 60 50 40 30 20 10 0 1 3 Expected of target Revised da Lead Direct	5 7 S	0 11 13 to meet	15 17 et stan	19 21 2: Tot	3 25 27 al		3 35 37 tory Smith	, Chie	cases				

Avoidable Pressure Ulcers – Grade 2

What is causing underperformance?	What actions have been taken to improve performance?	Target (mth	ly)	Latest perfori				YTD performa	ance		Forecast performance for next reporting period						
The incidence of pressure	In response to these	G2= 8			G2 = 1	0		G2 =	: 44			G2 =	= 8</td <td></td> <td></td>				
ulcers for August is out of trajectory targets for Grade 2 avoidable pressure	findings, Heads of Nursing will be requested to review the	Table one - A	voidal	ble Grad	e 2 Pre	essure	Ulcer	s April –A	ugust 2	015							
ulcers. Key findings from	provision of footstools	Threshold f	or Gra	ade 2 Av	/oidab	le Pre	ssure	Ulcers 2	015/16								
this month's validation	and heel protection	Month	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mai	· YTD		
events are that increased	equipment at ward level.	Threshold	8	8	8	8	8	8	8	8	8	8	8	8	96		
acuity and inadequate staffing levels have	The pressure ulcer prevention team together	Incidence	10	8	8	8	10								44		
resulted in interventions to	with the Anti-coagulation																
avoid pressure ulcers were	CNS will also focus work																
not completed consistently. A higher	with nursing and medical staff, to ensure the staff	Table two - A	voidal	ole Grad	e 3 Pre	essure	Ulcers	s April – A	ugust 2	2015							
number of heel damage	from the clinical areas	Threshold for Grade 3 Avoidable Pressure Ulcers 2015/16															
related pressure sores,	with avoidable HAPUs	Month	Apr	May	Jun	Jul	Aug	g Sep	Oct	Nov	Dec	Jan	Feb	Mar	YTD		
appears to be due to	related to inappropriate	Threshold	6	6	6	6	6	6	6	6	6	6	6	6	72		
inadequate heel protection mostly when the patients	use of anti embolic stockings (AES) have	Incidence	3	0	4	1	4								12		
were nursed in chair. Some clinical areas	had update / training on correct use of AES and	Table three -								<u>2015</u>							
reported not elevating legs	contraindications.	Threshold f	or Gra	ade 4 Av			ssure	Ulcers 2	015/16								
through a lack of	Matrons will be auditing	Month	Apr	May	Jun	Jul	Au	g Sep	Oct	Nov	Dec	Jan	Feb	Mar	YTD		
footstools. A strong theme this month is also	and promoting the use of the UHL DVT prevention	Threshold	0	0	0	0	0	0	0	0	0	0	0	0	0		
inappropriate use of anti	checklist to ensure safe	Incidence	0	0	0	0	0	0							0		
embolic stockings.	use of anti-embolic stockings.	Expected d	ate to	meets	standa	ard /					<u> </u>		J				
		target						Septemb	per 201	5							
		Revised dat				d		ТВА									
		Lead Direct	or / L	ead Of	ficer			Julie Sm Michael	,			sing					

Outpatients Friends and Family test – Coverage

What is causing underperformance?	What actions have been taken to improve performance?	Target (mthly / end of year)	August performa	ance	YTD performance	Forecast performance for next reporting period
A clear system for the collection of Friends and Family Test results has been established within the three main outpatients'	Clinical Management Group Senior Management Teams have been highlighted to these results and asked to increase coverage	Q1 - 3% Q2/3 - 4% Q4 - 5%	1.	4%	1.3%	1.3%
departments as well as the majority of all stand-alone clinic facilities. Staff within these departments	and respond directly to patient feedback at clinic level.	CMG			August 20 ⁴	5
have been cited to the coverage	Senior Clinical Management Groups management teams are			% Rec	ommend	% Coverage
requirements, to ensure success:	increasing staff awareness of the requirement to collect feedback.	CHUGGS		9	1%	1.1%
Improve ownership and		CSI		9	7%	0.3%
monitoring of the Friends and Family Test within the Clinical	Feedback highlighted to Clinical Management Groups through	ESM		9	4%	0.5%
Management GroupsIncrease medical staff	Executive Team meetings and Executive Quality Board.	ITAPS		1(00%	0.5%
engagement and ownership		MSKSS		g	2%	3.6%
Review Clinic Clerk activity and	CHUGGS, MSKSS, Alliance and W&C have all shown improvement	RRCV		g	7%	1.2%
resource to ensure staff have time to direct patients to the touch	in coverage from July to August with ESM, RRCV and CSI	WC		9	6%	1.4%
screens to complete the Friends and Family Test	showing deterioration.	The Alliance			-	_
		UHL		g	3%	1.4%
		Expected date to r	neet	Quarter	3	
		standard / target Lead Director / Lea	d Officer		ith Chiof Nurse	
		Lead Director / Lea	a Officer		ith, Chief Nurse Leatham, Assistan	Chief Nurse

% staff with an annual appraisal

% staff with an annual appraisal What is causing underperformance?	What actions have been taken to improve performance?	Target (mthly / end of year)	Latest month performance) performa	ance		t performa reporting	
 There has been a slight deterioration over the last month, from 89.12% to 88.78 % 	 Discussion at CMG / Directorate Boards and across services / areas 	95%	88.78%		88.8%	6	As show		
(against a target of 95%)	2. Circulation of breakdown of	Performa	nce by CMG						
	performance by cost centre	CMG		Feb-15	Mar-15 A	pr-15 May	y-15 Jun-15	Jul-15 A	Aug-15
	covering review period	Alliance Elec	ctive Care	96.27%			93% 89.93%		4.19%
2. Feedback from Clinical	3. Making It All Happen meetings	CHUGGS		94.83%	94.58% 9	5.20% 93.8	84% 94.18%	92.97% 92	2.97%
Management Group and	are being held in all areas.	Clinical Supp Services	oort & Imaging	95.47%	97.21% 9	7.52% 96.8	80% 95.30%	94.07% 94	4.00%
Directorates Leads indicates	4. Confirm and Challenge		& Specialist Medicine			4.96% 83.9			4.89%
that the reduction in	meetings in the CMGs,	ITAPS		93.04%			22% 88.58%		2.30%
performance is caused by:-	performance reports cover	MSK & Spec	cialist Surgery	92.64%	94.21% 93		70% 91.84%		95.50%
	appraisal performance and actions.		iratory & Cardiac	88.04%		7.26% 86.0			0.45%
a. Line manager /	5. Performance management	Women's &	Children's	88.25%			<u>28%</u> 83.12%		9.22%
appraiser omissions in	being pursued for areas that	CMGS Corporate A	r025	91.18% 89.52%			40%89.56%96%82.91%		89.18% 84.69%
data return	persistently remain below 95%	Total	leas	91.03%			30 % 82.91 % 74% 88.97%		8.78%
b. Reporting issues across some staff groups and	 Recovery plans in place across all underperforming areas with 		ecast for the n						
Alliance	trajectories set (at appraisee /	CMG			Sept	Oct	Nov		
c. Service pressures	team level)	Alliance			90%	92%	95%		
preventing the release	Recovery plans monitored	CHUGGS			94%	95%	95%		
of staff to conduct or	against set trajectories	Clinical Supp	port & Imaging Servic	es	95%	95%	95%		
attend appraisal	8. Review of management	Emergency	& Specialist Medicine	;	90%	93%	95%		
d. Re alignment of	structures to ensure appropriate	ITAPS	·		92%	94%	95%		
appraisal date with incremental pay	devolving and span of control for direct staff	MSK & Spec	cialist Surgery		95%	95%			
	9. Clear expectations set regarding	Renal, Resp	iratory & Cardiac		95%	95%	95%		
	reporting requirements	Women's &	Children's		90%	92%	95%		
	10. Close monitoring at a local level	Corporate			92%	95%	95%		
	on a weekly basis	Expected	date to meet	Novembe	er 2015				
		standard							
		standard	late to meet						
			ctor / Lead		,		/orkforce A	nd	
		Officer			tional Dev				
				Bina Kote	echa. Assis	stant Dire	ctor of Lear	ning and O)[]

52 week breaches - incompletes

What is causing underperformance?	What actions have been taken to improve performance?	Target (mthly / end of year)	July performance	YTD performance	Forecast performance for next reporting period
261 patients have breached/ continue to breach 52 weeks in the	The service is now closed to new referrals with some	0	258	258	c. 260
 Orthodontics department. 258 patients are on an incomplete pathway; 3 patients' non-admitted pathways ended in August. The reasons for this underperformance are as follows: Incorrect use and management of a planned waiting list for outpatients. Inadequate capacity within the service to see patients when they are ready for treatment. There are currently 11 patients on the waiting list between 40 and 51 weeks, who are likely to roll over to become 52 week breaches. 	 clinical exceptions. Funding has been secured from NHS England for 2 WTE locums to clear backlog. 1 application has been received; while this individual is not suitable for a consultant post, they will be interviewed for a middle grade post. NHS England contacting pathway providers to see if able to treat any of these patients in the community. Clinical review of the service by Mr Matthew Metcalfe. A Serious Untoward Incident (SUI) investigation has taken place and recommendations will be a published in the next. 	review of planned been taken Trust • Communicat • System revie • All General review and a • Weekly revie	I waiting lists at spec wide: ion around planned v w of all waiting list c Managers and Head ssurance of all waiting w at Head of Ops m	ialty level. Therefore the waiting list management odes; ds of Service have sign ng lists, to be returned to eeting for assurance;	to all relevant staff; ned a letter confirming
	 will be published in the next few weeks. The Orthodontics department at Northampton General Hospital has indicated they will be able to take c.60 	Expected date to standard / targe			
	patients to be treated there. So far 55 patients have agreed to transfer their treatment to NGH, with efforts to identify another 5 continuing.	Lead Director / L Officer		Mitchell, Chief Operatin aghan, Director of Perfo ion	

6 Week Diagnostic Test Waiting Times

What is causing underperformance?	What actions have been taken to improve performance?	Target (mthly / end of year)		rmance Alliance)	-	YTD performance (UHL Alliance)		st nance for porting
Imaging The majority of imaging diagnostics are	Imaging A plan is well developed and part	<1%	1	3.37%	1	3.37%	4	.5%
delivered within 6 weeks; the exception to this has been a small volume of complex cardiac CT (c.10 per month) and complex cardiac MRI (c.100 per	implemented to eradicate the Cardiac CT/ MRI issue by the end of September 2015. The DEXA service has created 35 additional slots weekly by employing a healthcare	The following per month fo	or 15-16:				diagnostic	breaches
month). As a tertiary centre UHL is one of a small number of Trusts that provides this service. 239 MRI and CT breaches were reported in August	assistant, allowing the service to reduce appointment lengths. Therefore no breaches are expected in September.	2000	UHLAII	iance Diagnost	ic Breaches	2015-16	-	
2015; this inflated number is due to capacity constraints in particular cardiac MRI.	Endoscopy In order to address long patient waits, UHL are working with Medinet to put on weekend	1400				1		
152 patients awaiting DEXA scans breached six weeks at the end of August as a result of receiving c.500 referrals when the service has capacity	lists, providing 60-90 additional scopes per weekend. The department is also in the process of transferring 300 patients to Circle, as well as approximately 100 patients to Nuffield. Additional lists have	1000						
for c.400 scans, this was compounded by some unplanned scanner downtime during the month.	also been put on by UHL's own consultants. The Trust will also be part of an initiative led by the Tripartite around securing extra	200 0 A	.pr-15	May-15	Jun- 1 5	Jul-15	Aug-15	
Endoscopy An issue with planned waiting lists in Endoscopy surfaced in May 2015.	capacity within the Independent Sector and other NHS Trusts for Endoscopy, UHL has submitted its requirements for this process		Imaging (incl	DEXA) 📕 Er	ndoscopy	Other	Total	
Following validation, the number of breaches was found to be higher than	but awaits the implementation. The extra capacity is complemented by a	The table to the table table to the table ta			e percen	itage of b	oreaches	as share
originally first thought, meaning that we have reported 1479 breaches for	robust action plan aimed at addressing general performance issues in		Apr- 15	May-15	Jun- 15	Jul-15	Aug-15	YTD
August 2015 across flexible	Gastroenterology, with particular focus on	UHL	0.92%	0.61%	6.97%	12.40%	14.92%	14.92%
sigmoidoscopy, gastroscopy and colonoscopy. Capacity and demand review in Endoscopy has identified that	ensuring that all lists are fully booked and efforts to improve Cancer performance via	UHL Alliance	0.83%	0.59%	6.16%	10.92%	13.37%	13.37%
the Trust is short of approximately 8-10 lists per week.	access to Endoscopy tests. There has also been a management review in the department and an Endoscopy Manager	Expected date to meet			October 2015			
	has been appointed to focus solely on the service.				Richard Mitchell, Chief Operating Officer			·

Suzanne Khalid, Clinical Director CSI

Cancelled patients not offered a date within 28 days of the cancellations UHL

What is causing underperformance?	What actions have been taken to improve performance?	Target (monthly) 1)On day=0.8% 2) 28 day = 0	Latest month performance – June 15	YTD performance (inc Alliance)	Forecast performance for next reporting period
Despite capacity pressures, the OTD cancellation percentage significantly compared to last month (0.7%). The main five reasons for cancellation were: • Lack of theatre time(30) • Equipment failure(7) • Paediatric bed	List over runs form a significant risk to OTD performance. The process of exception reporting is now better able to identify any over booked lists by the theatre managers working with theatre staff. To reduce risks of cancellations a number of actions have been	 0.7% (0.7% -UHL & 0.0% Alliance) 5 (4 from Urology and 1 General Surgery) 	1) 1.3% (1.3%- UHL &1.0% Alliance) 2)1UHL	1) 0.9% (0.9% - UHL & 0.9% Alliance) 2) 9	1) 0.8 % 2) 1 to
 Indediatine bed unavailability(6) Critical care bed Unavailability (6) Staff unavailability(5) There were four Urology patients and General Surgery patients who breached the 28 day rebooking target. This was due to an increase in the number of cancer cases that created capacity problems in ITU. Four patients have now had their operations and one patient is waiting to have their surgery on the week commencing 16th September. 	identified and are in the process of implementation. Theatre managers have increased theatre capacity for the increased cancer demand by making additional lists available. The ITAPS and CHUGGS Senior Managers are working together to improve theatre capacity in the long term. <u>Risks to delivery of recovery plan</u> The key risk remains failure to escalation of patients at risk of cancellation on the day, following the UHL cancelled escalation policy. For those cancelled on the day, it is vital that they adhere to the Trust policy of escalating to CMG, Head of Operations for resolution, prior to agreeing any cancellations.	1.0%	standard / On th	1.8% 1.6% 1.0% 0.8% 0.7% 0.7%	2% 1.1% 1.30% 2% 0.9% 0.7% 0.70% 0.60%
		Lead Director / Lead Off		ard Mitchell, Chief Ope Walmsley, Deputy Dire	

NHS e-Referral System (formerly known as Choose and Book)

What is causing underperformance?	What actions have been taken to improve performance?	Target (mthly / end of year)	August performance	YTD performance	Forecast performance for next reporting period
The Trust is measured on the % of Appointment Slot Unavailability (ASI) per month.	 Action plan An action plan has been written outlining steps for recovering performance; This has been shared with 	<4%	Unable to report	Unable to report	No forecast as unable to measure
 UHL has not met the required standard of <4% for approximately two years. When it has been able to reach this standard, it has not been sustainable. The two most significant factors causing underperformance are: Shortage of outpatient capacity; Inadequate training and education of administrative staff in the set up and use of the NHS e-Referral System. The specialties with the highest number of ASIs are: General Surgery; Rheumatology; 	 This has been shared with commissioners. Capacity Additional capacity in key specialties is part of RTT recovery plans. Training and Education Training and Education of staff in key specialties continues, to ensure that the system is adequately set up and administrative processes are fit for purpose; Meetings are taking place with the specialties experiencing the highest rate of ASIs, focusing on awareness raising and seeking named accountability. 	from Choose a releasing weel available is fro This means th	and Book, the HSCI kly ASI data until at m the week ending	C have indicated least October 20 7 th June and ther	enced post-cut over that they will not be 015. The latest data refore is out of date. track and report on
 Orthopaedics; ENT; Gynaecology. Transition to new e-Referral System: Choose and Book migrated to the new e-Referral System on Monday 15th June; 	 Current focus is on working with specialties with no known capacity problems, but high ASI rate to raise awareness and promote accountability. Additional resource to support the e- Referral System 	Expected date to meet standard / target	December 2015		
• The challenges experienced in the period after the cut-over have calmed down considerably with installation of Google chrome improving the speed of the system.	 An NHS e-Referral System administrator has been in post since May; She will be working with key specialties to help reduce their ASIs and promote administrative housekeeping. 	Lead Director / Lead Officer	Richard Mitchell, C Will Monaghan, Di Information		

Ambulance handover > 30 minutes and>60 minutes

		Target	August	t YTD	Forecast
What is causing underperformance?	What actions have been taken to improve performance?	0 delays over 30 minutes	>60 min 9 30-60 mir 17%		> 60 min 6% 30-60 min – 17%
Difficulties continue in accessing beds from ED leading to congestion in the assessment area and delays ambulance handover. May's performance remained similar to the preceding month but an improvement on the Q4 performance.	has been published and is being	30%	Ambulance Handor	ne 15) +Ambulance Handover >60 Mins (C	AD+ from June 15)

Cancer Waiting Times Performance

What is causing underperformance?	What actions have been taken to improve performance?	Target end of	t (mthly / year)	Latest mont performanc July			Forecast performance for August
R8: 2 Week Wait 2WW performance dropped by 3.6% from	R8: 2 Week Wait The Trust is working intensively with the Endoscopy Department in order to address the current	R8: 2V (Targe	VW et: 93%)	87.5%	8	9.4%	88%
the July position and remains under target. The key reason for underperformance is	underperformance with a robust action plan. More broadly, the Trust is working with CCGs to improve the		61 day 1 st et: 96%)	97.2%	9	5.7%	96%
Endoscopy; if 2WW performance for Upper and Lower GI were removed from the Trust position, this standard would	quality of 2WW referrals, specifically in relation to correct process, use of appropriate clinical criteria, and preparation of patients for the urgency of	(Targe	Surgery et: 94%)	92.2%	8	9.9%	90%
have been achieved.	appointments. R12: 31 day subsequent (surgery)	R14: 6 RTT (Targe	52 day et: 85%)	73.7%	- 7	6.1%	78%
R12: 31 day subsequent (surgery)31 day subsequent (surgery) was failed	It has been agreed that all escalated Cancer patients coming into theatre should be escalated to the General Manager for Theatres to ensure that they are	R15: 6 screer (Targe		95.2%	90	0.8%	90%
predominantly as a result of Urology performance. The main factor is inadequate elective capacity.	appropriately prioritised. The Cancer action plan aims to address the step-down of patients from Intensive Care, in order to pull Cancer	Perfo	ormance k	oy Quarter			
	patients through the system more quickly. It also		14/15 FYE	15/16 Q1	15/16 Q2	15/16 Q3	15/16 Q4
R14: 62 day RTT	includes significant investment in more clinical staff, including a nurse specialist in Urology and consultants	R8	92.2%	90.1%	87.5%		
62 day performance has dropped by	in Head and Neck and Dermatology. This additional	R10	94.6%	95.1%	97.2%		
10.5% between June (84.2%) and July	capacity will impact positively on performance.	R12	89%	89.1%	92.2%		
(73.7%), however more positively the	R14: 62 day RTT	R14	81.4%	76.9%	73.7%		
number of the patients in the 62 day backlog has reduced by 12% over the	Efforts to improve 31 day and 2WW performance will help to improve the 62 day position. The Endoscopy	R15	84.5%	89%	95.2%		
same period.	action plan will improve performance, with daily conversations between service manager/ cancer navigator, and the authority for the service manager to prioritise 2WW patients before all other patients on waiting lists. The appointment of 3 band 7 staff with key responsibility for managing cancer pathways in our worst performing tumour sites will provide the key focus required. One is in post, one appointed (starting in November) and interviews for the third will be in September. The IST review was generally positive about the structures and processes that UHL has and is planning to have in place, with a number of key recommendations which will be implemented. Weekly executive scrutiny of 62 day backlog reduction plans was initiated in September, led by the COO.	meet target Revis meet Lead	cted date t standard / ed date to standard Director / Officer	 R10: Red R12: Red R14: Red risk) R15: Red Richard 	covery exp covery exp covery exp covery exp Mitchell, C	bected July bected Sep bected Oct bected Jun bected Jun	otember 2015 ober 2015 (at

Cancer Patients Breaching 104 days What actions have been taken to improve What is causing underperformance? Month by month breakdown of patients breaching 104 days performance? The number of patients breaching 104 days on a 62 day pathway is at 60% of the August level, The table and graph below outline the number of Cancer 12 Cancer patients on the 62 day pathway marking a significant improvement. The most patients breaching 104 days by month for 15-16: breached 104 days at the end of July, which improved tumour site is Lung. is much improved from the end of August May-15 Apr-15 Jun-15 Jul-15 Aug-15 position. Number Number of patients Given the poor 62 day performance specifically Tumour site of patients 12 20 12 in Lung, Lower GI and Urology, funding for 10 12 breaching 104 days breaching three band 7 Cancer Delivery Managers has Urology 104 days 3 been identified to support them. The Urology Lung 1 manager is in place, the Lower GI manager will NB: not all patients confirmed Cancer 5 Lower GI start in November and the Lung post is 2 Upper GI currently being re-advertised. They will jointly report to CMG management teams and the 1 Breast Number of patients breaching 104 days Cancer Centre. This dedicated full-time service management will improve Cancer performance 25 The following factors have significantly over the medium term. 20 contributed to delays 15 No. patients Reason This is complemented by an overarching action Patient initiated delays 2 plan aimed at improving Cancer performance 10 across the Trust involving central actions from 3 Patient unfit 5 the Cancer Centre management/ ODU as well 1 Tertiary referral 0 as improvements at tumour site level. Kev Patient co-morbidities/ May-15 Jun-15 Jul-15 Aug-15 Apr-15 central actions include: requiring high risk 2 • Introduction of stamps to ensure that assessment NB: all patients breaching 104 days undergo a formal 'harm Cancer patients' Pathology samples are 2 Endoscopy delays review' process and these are reviewed by commissioners appropriately prioritised; Patient receiving other 2 • Escalation of any pathway delays of treatment first more than 96 hours to the Director of Performance and Information: Expected date to meet standard / N/A • All Cancer patients coming into theatre target to be escalated to the General Manager Revised date to for Theatres: N/A meet standard To establish CMG / Cancer Centre agreement on a Standard Operating Richard Mitchell, Chief Operating Officer Lead Director / Procedure. Lead Officer Matt Metcalfe, Clinical Lead for Cancer

CQC – Intelligent Monitoring Report

The latest CQC Intelligent Monitoring Report (IMR) was published on the CQC website on the 29th May 2015.

The IMR evaluates against a range of indicators relating to the five key questions used by the CQC as part of their inspections - is the organisation safe, effective, caring, responsive, and well-led?

Within each area of questions a set of indicators has been developed and each indicator has then been analysed to identify the following levels of risk for each organisation:

- 'no evidence of risk'
- 'risk'
- 'elevated risk'

Truct Ourse						Un	iversity Hospita	Is of Leicester NHS Trust		
Trust Sumi	mary								Priority banding for inspection	4
			c	ount of 'Risks	and 'Eleva	ted risks'			Number of 'Risks'	5
									Number of 'Elevated risks'	1
Overall								Risks	Overall Risk Score	7
		-						Elevated risks	Number of Applicable Indicators	95
L								Elevated risks	Percentage Score	3.68%
0		1	2	3	4	5	6	7	Maximum Possible Risk Score	190
									а 	

Safe	Never Event incidence	Risk
Effective	PROMs EQ-5D score: Groin Hernia Surgery SSNAP Domain 2: overall team-centred rating score for key stroke unit indicator	Risk Risk
Responsive	Composite indicator: A&E waiting times more than 4 hours	Elevated risk
Well-led	TDA - Escalation score GMC - Enhanced monitoring	Risk Risk

CQC Indicator	Risk Level in latest IMR	UHL Response
Compose indicator: A&E	Elevated risk	Overall performance for the year was 89.1% compared to 88.4% in 2013/14. Although our absolute
waiting times more than 4		performance was broadly stable, our relative performance improved markedly, moving us from the
hours (01-Oct-14 to 31-	(Risk in the last report)	bottom 10 of the 140 A&E providers to mid-table. Nevertheless, the standard is 95% and we need to do
Dec-15)		more to get there, hence the continued focus on emergency care in our priorities for 2015/16. Work has
		started on building a larger ED to meet demand. This is due to be completed by December 2016. Full
		action plan monitored at Urgent Care Board.
Never Event incidence (01-	Risk	There were 4 Never Events escalated during this period, these were:
Feb-14 to 31-Jan-15		Wrong site surgery – wrong toe
	(New risk since last report)	Wrong size implant/prosthesis – hip implant
		Retained foreign object post-procedure - swab tie
		Retained foreign object post-procedure -vaginal swab
		All four received a full RCA investigation with robust action plans. Actions will be monitored through to
		completion by the Adverse Events Committee.
PROMs EQ/5D Score:	Risk	We've improved our patient information and more recent data is in line.
Groin Hernia Surgery (01-		
Apr-13 to 31-Mar-14	(No change from last report)	
SSNAP Domain 2: Overall	Risk	This remains at a D and showed some deterioration. This was primarily due to not getting the patients
team-centred rating score		to the stroke unit in 4 hours and not meeting 80% having 90% stay on the stroke unit. This was partly
for key stroke unit indicator	(New risk since last report)	due to the global pressures on emergency care. We have since updated our bed management policy
(01-Jul-14 to 30-Sep-14)		with support from the trust and aim to have 4 beds available overnight and be the last medical outlying
		ward on the unit with pts due to be discharged the next day. This is reaping results as shown by the
		DIY Q4 result. Work has also been ongoing on our discharge process and we now have a coordinated
		conference call with all rehab stroke units and ESDS which is working well.
TDA Escalation score (01-	Risk	Continue to implement the remedial actions to achieve compliance with the NHS TDA Accountability
Nov-14 to 30-Nov-14)		Framework 2015-16 in line with the timescales stipulated in the Trust's oversight self-certification return
	(Unchanged since last report)	to work which is reviewed and confirmed monthly by the Trust Board at its public meetings and
		submitted to the NHS TDA.
GMC enhances monitoring	Risk	Emergency Medicine and Renal Medicine remain under enhanced monitoring. Ophthalmology is also
(case status as at 23-Mar-		under enhanced monitoring but as a region-wide issue, which happens to include Leicester.
15	(Unchanged since last report)	

15/16 Quality Schedule and CQUIN Indicators - Confirmed RAGs for Q1 and Anticipated RAGs for Q2 15/16

Schedule Ref	Indicator Title	Q1 RAG	Predicted Q2 RAG	Commentary
	QUALITY SCHEDULE			
PS01	Infection Prevention and Control Reduction.	G	G	Although C Diff above monthly threshold for Aug by one case, still on track to achieve end of year threshold
PS02	HCAI Monitoring	G	G	0 MRSA Bacteraemias
PS03	Patient Safety	G tbc	G	0 Never Events. Full patient safety report to be submitted to the Sept CQRG meeting.
PS04	Duty of Candour (DoC)	G	G	0 Breaches in respect of Moderate or Serious Incidents. Details of audit plans submitted to commissioners
PS05	Complaints and user feedback Management (excluding patient surveys).	G tbc	G	Improved performance against response times. Full Complaints Management report to be submitted to the Sept CQRG meeting
PS06	Risk Assurance	G	G	Further assurance provided where Risks not reviewed at time of reporting to EPB. All CAS alerts responses and actions on track.
PS07	Safeguarding	tbc	tbc	Reports submitted – for review by the CCG Safeguarding team – further assurance requested relating to Mental Capacity Act actions.
PS08	Reduction in Pressure Ulcer incidence.	G	Α	0 G4s and G3s below threshold. Above G2 threshold in August. Exception report submitted.
PS09	Medicines Management Optimisation	G	tbc	Q1 Red RAG for Controlled Drugs Audit as results below 95% but commissioners noted improvements made. Green for other parts of Indicator. Q2 RAG dependent upon Medicines Code audit results showing improvement.
PS10	Medication Errors	A	G	Less reported errors in Q1 compared to Q4 and threshold is to report increased number of Medication Errors. Agreed to review UHL's reporting rate with other trusts. Actions being taken to reduce harm noted.
PS11	Safety Thermometer	G	tbc	% for Harm Free Care below 95% standard in July and August and below Q1 average.
AS01	Cost Improvement Programme (CIP) Assurance	A	G	Commissioners noted UHL's plans for ongoing monitoring of the impact of CIPs on quality but Red RAG for Q1 as several delays with implementation of proposed process.
AS02	Ward Health-check	G	G	Evidence of actions being taken where Wards either below agreed staffing levels or not meeting Clinical Measures Scorecard targets
AS03	Nurse Revalidation Programme	G	G	Assurance provided about plans in place to meet revalidation requirements
AS04	Staffing governance	Α	Α	Progress against OD Plans noticed but Amber RAG due to non achievement of

Schedule Ref	Indicator Title	Q1 RAG	Predicted Q2 RAG	Commentary
				Appraisal and Mandatory Training
AS05	Involving employees in improving standards of care.	G	G	Q1 Report received and actions noted.
AS06	Staff Satisfaction	G	G	Staff satisfaction received with action plans in place and on track for areas of poor response.
AS07	External Visits and Commissioner Quality Visits	G	G	Q2 RAG dependent upon Actions (in response to recommendations made) being on track.
AS08	CQC Registration	А	G	Q1 Amber due to UHL not being reported as not fully compliant with CQC standards, however noted that action plan following the most recent visit is on track
CE01(a)	Communication - Content - Medical	G	G	Audit Schedule reported - ED letters Q1. Disch Letters Q1 - Q4. OutPt Letters - Q2-Q3.
CE01(b)	Communication - Content - Nursing	G	G	Nursing letter standards to be incorporated into Letters Policy and audit planned for Q3
CE02	Intra-operative Fluid Management	R	G	Threshold not achieved for Q1. Improved performance for July – now above thresholds
CE03a	Clinical Effectiveness Assurance - Audit	Α	G	Audit plan for 15/16 reviewed at UHL Clinical Audit Ctte . Q1 Amber due to audits being behind schedule
CE03b	Clinical Effectiveness Assurance - NICE	G tbc	G	UHL Compliant with all NICE TAGs. Reporting on Clinical Guidelines etc deferred to the October meeting.
	Women's Service Dashboard	A tbc	G	For reporting to the September CQRG. Q1 RAG anticipated to be Amber due to Obstetrician training and C Sections thresholds not being met.
CE05	Children's Service Dashboard	G tbc	G	For reporting to the September CQRG. SpR training threshold improved. Significant improvement in performance in May for 'timing of Assessment on CAU'
CE06a	PROMS - Patient Reported Outcomes	Α	G	UHL's participation in line with national average for both participation/outcomes for all procedures with exception of Groin Hernia where participation is below average.
CE06b	Consultant Clinical Outcomes	G	G	No outcomes published since reported for Q4. UHL outcomes better than average or within expected.
CE07	#NOF - Dashboard	R	A	time to theatre' not achieved for any Month in Q1. Performance improved in June but still below the 72% threshold. Below threshold for July but above in August
CE08	Stroke and TIA monitoring	G	G	Improvement in '90% stay' and also in overarching SSNAP Domain. Further improvements to be made for Therapy related targets - business case approved to recruit additional staff
CE09	Mortality	G	G	Published SHMI for Jan to Dec 2014 = 99 (ie below 100). Progress being made with plans to meet NTDA requirement to screen all deaths.
CE10	VTE Risk Assessment	G	G	95% threshold achieved for Q1 and July/August.
CE11	Venous Thrombo-embolism – Hospital Acquired RCAs	G tbc	G	For reporting to the September CQRG. RAG dependent upon commissioners agreeing to revised threshold for RCAs of post discharge Hospital Acquired VTEs.

Schedule Ref	Indicator Title	Q1 RAG	Predicted Q2 RAG	Commentary
				requirement to review all Hospital Acquired VTEs (both inpt and post discharge)
CE12	Nutrition and Hydration	R	Α	Q1 Thresholds achieved for all CMGs with the exception of ESM. Actions in place to address and CMG implementing several initiatives to support patients' nutritional needs but not necessarily captured by the metrics.
CE13	Food Strategy	deferred	N/A	Delays with finalising Food and Drink Strategy due to capacity issues with lead authors.
CE14	Community Acquired Pneumonia	А	G	CURB and Chest Xray achieved but Timing of Antibiotics just below threshold. Increased activity seen in Q1.
CE15	Improving End of Life (EoL) care.	G	G	Continued embedding of AMBER care bundle.
CE16	Heart Failure	А	G	Q1 Threshold not achieved. Plans in place to address in Q2.
PE01	Same Sex Accommodation Compliance and Annual Estates Monitoring	G	G	0 Breaches in Q1 or to date in Q2
PE02	Patient Experience, Equality and Listening to and Learning	G tbc	G	For reporting to the September CQRG. Continued triangulation of patient feedback and actions being taken in response
PE04	Equality and Human Rights	А	G	Q1 RAG due to lack of progress with capturing demographic data for patients with Learning Disability.
PE5	MECC	G	G	Referrals to STOP and Alcohol Liaison continue. MECC activities within Well-being at work continue.
PE6	Friends and Family Test	tbc	G	Thresholds met for Adult patients and improvement seen for Children's response rates in Inpatients but drop in participation for ED.
	SPECIALISED SERVICES QS			
SQ01	National Quality Dashboards	G	G	Confirmation being sought that all relevant Specialities are submitting data
SQ02	National Clinical Registries	G	G	Confirmation being sought that all relevant Specialities are submitting data
SQ03	HIV: GP registration and communication	G	G	Letters are sent at each medical clinic (at least once per year)
Z	NATIONAL CQUINS			
Nat 1	AKI Discharge Care Bundle	G	G	Quarter 1 is to provide baseline data about number/% of discharge letters containing details of AKI Stage and actions taken. Q2 RAG dependent upon threshold set.
Nat 2a	Sepsis - Screening	G	G	Q1 is to provide baseline data on number/% of em patients screened for sepsis. Provisional data shows small number of em patients in sample meeting criteria for screening with few being screened. 66% screened.

Schedule Ref	Indicator Title	Q1 RAG	Predicted Q2 RAG	Commentary
Nat 2b	Sepsis - IV Antibiotics	N/A	G	No threshold for Q1. Q2 threshold relates to provision of baseline data.
Nat 3a	Dementia - FAIR	G	G	90% threshold achieved for April and May
Nat 3b	Dementia Training	G	G	New clinical lead confirmed and training programme agreed. % of Medical Staff undertaking Category A/B training is low. Agreed to review threshold relating to junior doctors.
Nat 3c	Dementia Carers	G	G	Surveys undertaken and actions carried out in response to feedback received
Nat 4	Ambulatory Care - CDU	G	G	Q1 threshold is to confirm scope of scheme and improvement thresholds. Proposed to implement ACP in CDU – Q2 RAG dependent upon clinical staff capacity to continue with pilot.
	LOCAL CQUINS			
Loc 5	Readmissions	G tbc	G	Following review of Readmissions data, focused case note review undertaken and actions agreed. RAG tbc following review of Report submitted.
Loc 6	CHC Assessments completed	G	Α	Baseline data submitted. Q2 performance anticipated to be below 95% threshold.
Loc 7a	Safety Briefings	G	G	Commissioners looking to agree outcome measures for Q4.
Loc 7b	Increase 'Near Miss' Reporting	G	G	
Loc 8	Think Glucose	G	G	Continued roll out of the Think Glucose programme
Loc 9	Bereavement F/U	G tbc	G	Bereavement Follow Up Service Leads appointed and scoping of service being undertaken. Further information requested for Q1.
Loc 10	Learning Disabilities - Pt Exp	G	G	Baseline data for patients who DNA appointments reported and progress with actions.
	SPECIALISED CQUINS			
SS1/CUR	CUR Tool	G	G	Requirements for Q1 agreed with Local Area Team. On track to achieve Q2 threshold. Q4 payment at risk if not able to negotiate amended implementation plan with National Team.
SS2/C6	Oncotype Testing	G	G	Oncotype tests requested.
SS3/TH4	Critical Care Delayed Discharges	G	G	Baseline data submitted and action plan to improve
SS6/IM7	Rheumatic Diseases Network	G	G	Details of proposed network reported.
SS7/TH7	Complex Orthopaedic Surgery Network	G	G	Details of proposed network reported.

Schedule Ref	Indicator Title	Q1 RAG	Predicted Q2 RAG	Commentary
SS8/HSS	ECMO/PCO Collaborative Workshop	G	G	Participation in HSS workshops confirmed
SS10/CB5	Haemoglobinopathy Network	G	G	Network meeting held.
SS11/WC1	<28 Week Neonates 2 yr follow up	G	G	Baseline data submitted and action plan to improve.